Sign In

Emily Mason-Osann

Postdoctoral Researcher at AstraZeneca

Emily Mason-Osann is a Senior Scientist at AstraZeneca working in oncology drug development.1 She completed her postdoctoral fellowship at AstraZeneca from January 2020 to October 2022, focusing on strategies for combining treatments in oncology.1 Mason-Osann earned her PhD in Biomolecular Pharmacology from Boston University School of Medicine, where she studied the Alternative Lengthening of Telomeres (ALT) pathway in cancer cells.1 Her research background includes work on targeted nanoparticles for cancer treatment and recombinant immunotoxin therapy.1 Currently, she is part of the bioscience team at AstraZeneca, applying her expertise in cancer biology and drug development to advance oncology treatments.1

Highlights

Identification of a novel gene fusion in ALT positive ...

Related Questions

What are Emily Mason-Osann's main research interests?
How did Emily Mason-Osann contribute to the development of oncology drugs at AstraZeneca?
What is the Alternative Lengthening of Telomeres (ALT) pathway?
What were the key findings of Emily Mason-Osann's PhD thesis?
How does Emily Mason-Osann's work impact cancer therapy?
Emily Mason-Osann
Add to my network

Location

Greater Boston